Navigation Links
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Date:4/7/2008

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the

Clinical Gold Standard Through 2016, According to a New Report from

Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on inhibiting/slowing the progression of structural damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are the attributes that most influence surveyed rheumatologists' prescribing decisions in the treatment of the disease. Clinical data and expert opinion shows that current and emerging therapies have no advantage in these attributes over the market sales leader, Amgen/Wyeth/Takeda's Enbrel.

The new report entitled Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High for Novel Agents finds that, through 2016, there are no therapies in development that will displace Enbrel as the clinical gold standard treatment for rheumatoid arthritis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability, and/or delivery features that are inferior when compared with Enbrel.

The overall efficacy of emerging therapies such as Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab is comparable to that of Enbrel, while the overall safety and tolerability for emerging therapies that include ocrelizumab and UCB's Cimzia are also comparable to that of Enbrel. However, the currently available clinical data for golimumab, ocrelizumab and Cimzia is not as robust or extensive as those available for Enbrel.

"While emerging therapies such as golimumab and Cimzia offer superior delivery to that of Enbrel due to improved dosing frequencies, these agents' overall efficacy, safety and tolerability, respect
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
2. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
3. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
6. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Casinos ... years, despite rising competition from international and online casinos. ... 2.9% over the five years through 2014-15. Greater per ... demanding more gaming services. Rises in discretionary income levels ... more money on non-essential items such as casino gambling ...
(Date:7/12/2014)... Canada (PRWEB) July 12, 2014 Sean Francis, owner ... throwing out special challenges to his clients. He’s also known for ... He recently found a way to combine the two and is ... raised $2,000 for the Boys and Girls Club. , The funds ... which started on June 23rd. Francis sent out emails and asked ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with ... questions. Paddock tackles topics including main men's health ... longer than men, and testosterone replacement therapy, among others. ... featured on Doylestown Hospital’s website, Dr. Brad Paddock says, ... If you notice pain, bulging, or asymmetry in your ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Hospital investigators have found that an electrically powered amplification ... to the acute hearing of humans and other mammals. ... loss can result from malfunction of this amplification machinery ... as aspirin. , Sound entering the cochlea is detected ...
... May 7 The following is a,statement by ... The guidelines for smoking cessation released today ... reminder to the nation,s 45 million,smokers that they ... quit smoking and protect their health than ever ...
... Presbyterian Hospital of,Plano has been named a recipient ... state,s highest honor for quality and organizational,performance., ... health care facility,in Collin County to receive this ... is the first hospital in parent company Texas ...
... thwarted rewiring needed for neural development, mouse study shows ... class of weight-loss drugs that suppresses appetite by blocking ... caution in children, U.S. scientists report. , In research ... suppresses the adaptive rewiring of the brain necessary for ...
... GAINESVILLE, Fla. Retinas in newborn mice appear perfectly fine ... microRNAs except for one thing the retinas do not ... the absence of microRNAs in the mammalian eye, an international ... the Italian National Research Council describes a gradual structural decline ...
... As part of its ongoing,commitment to providing the ... is excited to welcome Katherine Anne Binns as ... New York office. KN will,draw particularly on her ... growing list of clients., "Katherine possesses the ...
Cached Medicine News:Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 2Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence 2Health News:MicroRNAs appear essential for retinal health 2Health News:MicroRNAs appear essential for retinal health 3Health News:Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks 2
... throughput primary or backup instrument, this ... and reliability equal to or greater ... advanced technology of the AUTION JET ... reproducible and accurate results, limiting interference ...
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone (E1) is one of the ... include estradiol and estriol. Estrone is produced ... adrenal cortex or gonads [1,2]. In premenopausal ... is secreted by the ovary. In prepubertal ...
Medicine Products: